Lymphoma Clinical Trials

Showing 721-740 of 3,379 trials

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05824585

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

Lymphoma, Non-Hodgkin

Dizal Pharmaceuticals230 participantsStarted May 2023

New York, New York, United States • Albury, New South Wales, Australia • Ballarat, Victoria, Australia +2 more locations

WITHDRAWNPhase 1/2

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

NCT06005649

This is a multi-center, open-label, single-arm, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (r/r B-NHL).

Non-hodgkin Lymphoma

Juventas Cell Therapy Ltd.Started Sep 2025

COMPLETED

Indolent Non Follicular Lymphomas Prognostic Project

NCT02904577

Prospective collection of data of possible prognostic relevance in patients with indolent non - follicular B-CELL Lymphomas.

Indolent B-Cell Lymphomas

Fondazione Italiana Linfomi - ETS370 participantsStarted Sep 2011

Vienna, Austria • Campinas, Brazil • Rio de Janeiro, Brazil +43 more locations

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Indolent Non Follicular Lymphomas Prognostic Project

Related Searches

Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

A Phase I Dose Finding Study of MB-CART2219.1

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies

Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma

64Cu-LLP2A for Imaging Hematologic Malignancies

Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma